Definitions of the levels of the recommendations (A, B, C, U) and classification of the evidence (Class I through Class IV) are provided at the end of the "Major Recommendations" field.
Hypersecretory Disorders
Conclusions
Botulinum neurotoxin (BoNT) is established as safe and effective for the treatment of axillary hyperhidrosis (two Class I studies), is probably safe and effective for palmar hyperhidrosis (two Class II studies) and in drooling in patients with Parkinson's disease (PD) (four Class II studies), and is possibly effective for gustatory sweating (five Class III studies). There is insufficient evidence to support the effectiveness of BoNT in hyperlacrimation (Class IV studies).
Recommendations
- BoNT should be offered as a treatment option to patients with axillary hyperhidrosis (Level A).
- BoNT should be considered as a treatment option for palmar hyperhidrosis and drooling (Level B).
- BoNT may be considered for gustatory sweating (Level C).
Neuro-urologic Disorders
Conclusions
BoNT is established as safe and effective for the treatment of neurogenic detrusor overactivity in adults (two Class I studies, one Class II study). Data on the use of BoNT for detrusor sphincter dyssynergia (DSD) are conflicting. BoNT is probably safe and effective for the treatment of DSD in patients with spinal cord injury (two Class II studies). However on the basis of one Class I study, BoNT does not provide significant benefit for the treatment of DSD in patients with multiple sclerosis (MS).
Recommendations
- BoNT should be offered as a treatment option for neurogenic detrusor overactivity (Level A).
- BoNT should be considered for DSD in patients with spinal cord injury (Level B).
Low Back Pain
Conclusions
BoNT is possibly effective for the treatment of chronic predominantly unilateral low back pain (LBP) (one Class II study).
Recommendation
BoNT may be considered as a treatment option of patients with chronic predominantly unilateral LBP (Level C).
Headache
Episodic Migraine
Conclusions
Based on published Class I and Class II studies, BoNT injection is probably ineffective in the treatment of episodic migraine (Level B).
Chronic Daily Headache
Conclusions
Based on inconsistent results from four Class II studies, there is insufficient evidence to support or refute a benefit of BoNT for the treatment of chronic daily headache (Level U).
Chronic Tension-type Headache
Conclusions
Based on the results of two Class I studies, at least one of which was adequately powered, BoNT injection is probably ineffective for patients with chronic tension-type headaches (Level B).
Recommendation
BoNT injections should not be considered in patients with episodic migraine and chronic tension-type headaches (Level B).
Definitions:
Classification of Recommendations
Level A = Established as effective, ineffective, or harmful (or established as useful/predictive or not useful/predictive) for the given condition in the specified population. (Level A rating requires at least two consistent Class I studies.*)
Level B = Probably effective, ineffective or harmful (or probably useful/predictive or not useful/predictive) for the given condition in the specified population. (Level B rating requires at least one Class I study or two consistent Class II studies.)
Level C = Possibly effective, ineffective, or harmful (or possibly useful/predictive or not useful/predictive) for the given conition in the specified population. (Level C rating requires at least one Class II study or at least two consistent Class III studies)
Level U = Data inadequate or conflicting; given current knowledge, treatment (test, predictor) is unproven. (Studies not meeting criteria for Class I–Class III).
* In exceptional cases, one convincing Class I study may suffice for an "A" recommendation if 1) all criteria are met, 2) the magnitude of effect is large (relative rate improved outcome >5 and the lower limit of the confidence interval is >2).
Classification of Evidence for Therapeutic Intervention
Class I: Randomized, controlled clinical trial with masked or objective outcome assessment in a representative population. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences. The following are required: a) concealed allocation, b) primary outcome(s) clearly defined, c) exclusion/inclusion criteria clearly defined, and d) adequate accounting for drop-outs (with at least 80% of enrolled subjects completing the study) and cross-overs with numbers sufficiently low to have minimal potential for bias.
Class II: Prospective matched group cohort study in a representative population with masked outcome assessment that meets b-d above OR a randomized controlled trial in a representative population that lacks one criteria a-d.
Class III: All other controlled trials (including well-defined natural history controls or patients serving as own controls) in a representative population, where outcome is independently assessed, or independently derived by objective outcome measurement.*
Class IV: Studies not meeting Class I, II, or III criteria, including consensus, expert opinion, or a case report.
*Objective outcome measurement: An outcome measure that is unlikely to be affected by an observer's (patient, treating physician, investigator) expectation or bias (e.g., blood tests, administrative outcome data).